Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)

被引：2
|
作者：
Abou-Alfa, Ghassan K.
Sangro, Bruno
Morse, Michael
Zhu, Andrew X.
Kim, Richard D.
Cheng, Ann-Lii
Kudo, Masatoshi
Kang, Yoon-Koo
Chan, Stephen L.
Antal, Joyce
Boice, Jillian
Xiao, Feng
Morris, Shannon R.
Bendell, Johanna
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Clin Univ Navarra, IDISNA CIBEREHD, Pamplona, Spain
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Harvard Med Sch, Boston, MA USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[8] Natl Taiwan Univ Hosp, Taipei, Taiwan
[9] Kinki Univ, Sch Med, Osakasayama shi, Osaka, Japan
[10] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[11] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[12] MedImmune, Gaithersburg, MD USA
[13] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS3103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3103
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
    Song, Xuyang
    Kelley, Robin Kate
    Khan, Anis A.
    Standifer, Nathan
    Zhou, Diansong
    Lim, KyoungSoo
    Krishna, Rajesh
    Liu, Lu
    Wang, Kun
    McCoon, Patricia
    Negro, Alejandra
    He, Philip
    Gibbs, Megan
    Kurland, John F.
    Abou-Alfa, Ghassan K.
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (04) : 754 - 763
  • [2] Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    Bendel, Johanna C.
    Kim, Tae -You
    Borad, Mitesh J.
    Yong, Wei-Peng
    Morse, Michael
    Kang, Yoon-Koo
    Rebelatto, Marlon
    Makowsky, Mallory
    Xiao, Feng
    Morris, Shannon R.
    Sangro, Bruno
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC
    De Toni, Enrico N.
    Mayerle, Julia
    Oehrle, Bettina
    Seidensticker, Max
    Rimassa, Lorenza
    Ehmer, Ursula
    Geier, Andreas
    Reiter, Florian P.
    Ettrich, Thomas Jens
    Philipp, Alexander B.
    Roessler, Daniel Christoph
    Ben Khaled, Najib
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS574 - TPS574
  • [4] Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    [J]. LIVER CANCER, 2022, 11 (02) : 87 - 93
  • [5] FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Patel, Timil H.
    Brewer, Jamie R.
    Fan, Jiaxin
    Cheng, Joyce
    Shen, Yuan-Li
    Xiang, Yue
    Zhao, Hong
    Lemery, Steven J.
    Pazdur, Richard
    Kluetz, Paul G.
    Fashoyin-Aje, Lola A.
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (02) : 269 - 273
  • [6] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
  • [7] Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC)
    Buchalter, Jemma
    Browne, Iseult
    Mac Eochagain, Colm
    Flynn, Calvin
    Carroll, Hailey Kathryn
    Galligan, Marie
    Bourke, Michele
    Lester-Grant, Amy
    Desmond, Fiona
    Hoey, Katherine
    Ryan, Ronan
    Cantwell, Colin P.
    McCann, Jeffrey
    McDermott, Ray
    MacNicholas, Ross
    Duffy, Austin G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).
    Buchalter, Jemma
    Evans, Niamh
    Browne, Iseult
    Mac Eochagain, Colm
    Flynn, Calvin
    Carroll, Hailey Kathryn
    Galligan, Marie
    Bourke, Michele
    Lester-Grant, Amy
    Hoey, Katherine
    Ryan, Ronan
    Cantwell, Colin P.
    McCann, Jeffrey
    McDermott, Ray
    MacNicholas, Ross
    Duffy, Austin G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16175 - E16175
  • [9] Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    de Castria, Tiago Biachi
    Khalil, Danny N.
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    [J]. FUTURE ONCOLOGY, 2022, 18 (33) : 3769 - 3782
  • [10] T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)
    Kelley, Robin Kate
    Lee, Young S.
    Conway, James
    Kurland, John F.
    Negro, Alejandra
    McCoon, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345